Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 10/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 9/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8651764 | 0.78 | GRIK1 (0.52) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| SCHEMBL8651762 | 0.78 | GRIK1 (0.52) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| SCHEMBL8656323 | 0.78 | GRIK1 (0.52) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| SCHEMBL8651768 | 0.78 | GRIK1 (0.52) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| SCHEMBL468961 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL8654703 | 0.76 | GRIK1 (0.50) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL8659016 | 0.76 | GRIK1 (0.50) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| Hydrochloric Acid SCHEMBL8654696 | 0.76 | GRIK1 (0.50) | PTGS1SLC7A11GSRGRIK1GRIK2 | |
| SCHEMBL4291341 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL8654700 | 0.76 | GRIK1 (0.50) | PTGS1SLC7A11GSRGRIK1GRIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | claimed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | claimed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | claimed |
| US-20100298352-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2010-11-25 | — | — | US | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298352-A1 | SMALL MOLECULE INHIBITORS OF CANCER STEM CELLS | TP53, TSG101, CDC7 | PTGS1 3697/4885SLC7A11 1269/4885GSR 2615/4885 |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | CDK14, CDK1, CCNB1 | PTGS1 2215/4885SLC7A11 2493/4885GSR 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.